0.00Open0.30Pre Close0 Volume7 Open Interest12.50Strike Price0.00Turnover501.53%IV72.97%PremiumAug 30, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.1914Delta0.0784Gamma24.67Leverage Ratio-0.1462Theta0.0001Rho4.72Eff Leverage0.0019Vega
Inovio Pharmaceuticals Stock Discussion
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet